SCHEMBL3408522

SCHEMBL3408522

Cc1cc(O)c2c(CCc3ccc4c(c3)CCO4)nn(C)c2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC5A2 P31639 4/20 0.62
▸ CHRM5 P08912 8/20 0.38
▸ CHRM1 P11229 8/20 0.38
▸ CHRM4 P08173 5/20 0.38
▸ CHRM3 P20309 4/20 0.38
▸ CHRM2 P08172 3/20 0.38
▸ SLC5A1 P13866 1/20 0.38
▸ RAB9A P51151 2/20 0.36
▸ PDE2A O00408 1/20 0.36
▸ ADRB2 P07550 1/20 0.35
▸ ADRB1 P08588 1/20 0.35
▸ ADRA2A P08913 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ KCNE1 P15382 1/20 0.35
▸ ADRA2B P18089 1/20 0.35
▸ ADRA2C P18825 1/20 0.35
▸ HRH2 P25021 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ ADRA1A P35348 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3413810 0.78 SLC5A2 (0.45) SLC5A2CHRM5CHRM1CHRM4CHRM3
SCHEMBL13108835 0.78 SLC5A2 (1.00) SLC5A2SLC5A1
SCHEMBL3405161 0.75 SLC5A2 (0.74) SLC5A2CHRM5CHRM1CHRM4CHRM3
SCHEMBL3405159 0.75 SLC5A2 (0.76) SLC5A2CHRM5CHRM1CHRM4CHRM3
SCHEMBL3405163 0.75 SLC5A2 (0.74) SLC5A2CHRM5CHRM1CHRM4CHRM3
SCHEMBL3410877 0.70 SLC5A1 (0.51) SLC5A2CHRM4SLC5A1RAB9ANPC1
SCHEMBL1276487 0.66 RAB9A (0.46) CHRM5CHRM1CHRM4CHRM3CHRM2
SCHEMBL29791018 0.66 PRKCI (0.49) CHRM5CHRM1CHRM4CHRM3CHRM2
SCHEMBL2035570 0.66 PRKCI (0.49) CHRM5CHRM1CHRM4CHRM3CHRM2
SCHEMBL14000463 0.65 RAB9A (0.43) CHRM5CHRM1CHRM4CHRM3CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816331-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA NV (BE) 2010-10-19 — — US disclosed
US-20100062971-A1 SUBSTITUTED INDAZOLE-O-GLUCOSIDES PATEL MONA 2010-03-11 — — US disclosed
US-20090099104-A1 SUBSTITUTED INDAZOLES-O- GLUCOSIDES PATEL MONA 2009-04-16 — — US disclosed
US-7511021-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-31 — — US disclosed
US-20060217323-A1 Substituted indazole-O-glucosides Tanabe Pharma Corporation (JP) 2006-09-28 — — US disclosed
US-7084124-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA, N.V. (BE) 2006-08-01 — — US disclosed
US-20050032711-A1 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032711-A1 Substituted indazole-O-glucosides GYS2, GPR119, UGGT1 SLC5A2 10/4885CHRM5 2983/4885CHRM1 4117/4885
US-20100062971-A1 SUBSTITUTED INDAZOLE-O-GLUCOSIDES GYS2, GPR119, UGGT1 SLC5A2 10/4885CHRM5 2983/4885CHRM1 4117/4885
US-20090099104-A1 SUBSTITUTED INDAZOLES-O- GLUCOSIDES GYS2, GPR119, PYGL SLC5A2 10/4885CHRM5 2312/4885CHRM1 3486/4885
US-20060217323-A1 Substituted indazole-O-glucosides GYS2, GPR119, UGGT1 SLC5A2 10/4885CHRM5 2983/4885CHRM1 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback